Thurston, Springer, Miller, Herd & Titak, Inc. Viking Therapeutics, Inc. Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $475 Million
- Q4 2024
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 3,500 shares of VKTX stock, worth $117,005. This represents 0.03% of its overall portfolio holdings.
Number of Shares
3,500
Previous 500
600.0%
Holding current value
$117,005
Previous $31,000
351.61%
% of portfolio
0.03%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
467Shares Held
63.2MCall Options Held
5.76MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$340 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$201 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$156 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$70.8 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$62.7 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.56B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...